腎結石的評估與處理

10.6666/ClinMed.202407_94(1).0079

蔡友蓮

腎結石（kidney stone disease） ； 尿路結石（nephrolithiasis） ； 尿液檢驗（urine chemistry）

臨床醫學月刊

94卷1期（2024 / 07 / 26）

450 - 459

繁體中文

腎結石，是一種尿液溶質產生結晶，堆積在尿腔中的疾病。腎結石的發生率逐年增加，更和全身性疾病有著密切相關，例如：代謝症候群、遺傳性疾病或內分泌疾病。透過尿液成分和結石成分分析，我們可以更了解結石的發病機轉，病生理，治療與預防。

1. Scales CD Jr, Tasian GE, Schwaderer AL, et al. Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health. Clin J Am Soc Nephrol 2016;11:1305-12."
   連結：
2. Vaughan LE, Enders FT, Lieske JC, et al. Predictors of Symptomatic Kidney Stone Recurrence After the First and Subsequent Episodes. Mayo Clin Proc 2019;94:202-10."
   連結：
3. Rule AD, Bergstralh EJ, Melton LJ, 3rd, et al. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 2009;4:804-811."
   連結：
4. Borghi L, Meschi T, Guerra A, et al. Essential arterial hypertension and stone disease. Kidney Int 1999;55:2397-406."
   連結：
5. Reiner AP, Kahn A, Eisner BH, et al. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J Urol 2011;185:920-5."
   連結：
6. Rule AD, Roger VL, Melton LJ, 3rd, et al. Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol 2010;21:1641-4."
   連結：
7. Khan SR, Canales BK. Randall's plaque and calcium oxalate stone formation: role for immunity and inflammation. Nat Rev Nephrol 2021;17:417-33."
   連結：
8. Daga A, Majmundar AJ, Braun DA, et al. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int 2018;93:204-13."
   連結：
9. Minotti B, Treglia G, Pascale M, et al. Prevalence of microhematuria in renal colic and urolithiasis: a systematic review and meta-analysis. BMC Urol 2020;20:119."
   連結：
10. Li X, Zhu W, Lam W, et al. Outcomes of long-term follow-up of asymptomatic renal stones and prediction of stone-related events. 2019;123:485-92."
    連結：
11. Dai JC, Pearle MS. Diet and Stone Disease in 2022. J Clin Med 2022;11."
    連結：
12. Daudon M, Frochot V, Bazin D, et al. Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment. Drugs 2018;78:163-201."
    連結：
13. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol 2014;192:316-24."
    連結：
14. Alexander RT, Fuster DG, Dimke H. Mechanisms Underlying Calcium Nephrolithiasis. Annu Rev Physiol 2022;84:559-83."
    連結：
15. Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int 2008;73:489-96."
    連結：
16. Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996;155:839-43."
    連結：
17. Li DF, Gao YL, Liu HC, et al. Use of thiazide diuretics for the prevention of recurrent kidney calculi: a systematic review and meta-analysis. J Transl Med 2020;18:106."
    連結：
18. Curthoys NP, Moe OW. Proximal tubule function and response to acidosis. Clin J Am Soc Nephrol 2014;9:1627-38."
    連結：
19. Witting C, Langman CB, Assimos D, et al. Pathophysiology and Treatment of Enteric Hyperoxaluria. 2021;16:487-95."
    連結：
20. Garrelfs SF, Frishberg Y, Hulton SA, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. 2021;384:1216-1226."
    連結：
21. Goldfarb DS. A woman with recurrent calcium phosphate kidney stones. Clin J Am Soc Nephrol 2012;7:1172-8."
    連結：
22. Rimer JD, Sakhaee K, Maalouf NM. Citrate therapy for calcium phosphate stones. Curr Opin Nephrol Hypertens 2019;28:130-9."
    連結：
23. Sakhaee K, Maalouf NM. Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol 2008;28:174-80."
    連結：
24. Shastri S, Patel J, Sambandam KK, et al. Kidney Stone Pathophysiology, Evaluation and Management: Core Curriculum 2023. Am J Kidney Dis 2023;82:617-34."
25. Betz MV, Penniston KL. Primary Contributors to Dietary Acid Load in Patients With Urolithiasis. J Ren Nutr 2023;33:53-8."